Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 14;11:1399. doi: 10.1038/s41598-021-80999-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

SHP2 blockade impairs the inhibitory effect of immunosuppressive myeloid cells. (a) Flow cytometry analysis of the absolute number of CD11b + myeloid cells per milligram tumor with different treatments in 4T1 syngeneic model. (b) Flow cytometry analysis of the absolute number of CD11b + myeloid cells per milligram tumor in 4T1-sgControl and 4T1-sgPtpn11 syngeneic model with different treatments. (c) Flow cytometry analysis of the absolute number of gMDSCs per milligram tumor with different treatments in 4T1 syngeneic model. (d) Flow cytometry analysis of the absolute number of mMDSCs per milligram tumor with different treatments in 4T1 syngeneic model. (e) Flow cytometry analysis of the percentage of gMDSCs over CD45+ cells in tumor tissues with different treatments in 4T1 syngeneic model. (f) Flow cytometry analysis of the percentage of M2-like macrophages over CD45+ cells in tumor tissues with different treatments in 4T1 syngeneic model. (g) Flow cytometry analysis of the absolute number of gMDSCs per milligram tumor in 4T1-sgControl and 4T1-sgPtpn11 syngeneic model with different treatments. (h) Flow cytometry analysis of the absolute number of M2-like macrophages per milligram tumor in 4T1-sgControl and 4T1-sgPtpn11 syngeneic model with different treatments. (i) Flow cytometry analysis of the percentage of CD11b+ CD33+ MDSCs over CD14+ monocytes after 5 days of GM-CSF and IL-6 induced MDSCs differentiation from monocytes with or without SHP099 treatment. (j) Flow cytometry analysis of the percentage of proliferating T cells after 6 days co-culture of differentiated MDSCs (treated with or without SHP099) with activated T cells (MDSCS:T cells = 1:2). T cells with diluted CFSE signal were gated. Percentage of T cells with diluted CFSE signal was labeled. Flow cytometry data was analyzed and processed with FlowJo (Version 10.7.1, https://www.flowjo.com/solutions/flowjo/downloads/previous-versions).